The big question surrounding Viking Therapeutics today centers around its promising glucagon-like peptide 1 (GLP-1) drug, ...

Viking Therapeutics (NASDAQ: VKTX) stock is soaring. Two years ago, the share price hovered just above $2. Today, shares ...

Fintel reports that on May 16, 2024, Raymond James upgraded their outlook for Viking Therapeutics (NasdaqCM:VKTX) from ...

Wells Fargo has released its annual biopharma M&A screen, identifying 31 potential acquisition targets in the ...

Viking Therapeutics (NASDAQ: VKTX), a clinical-stage company focused on developing novel therapeutics for metabolic and ...

Breaking this down further, VK2735 might be a $30 billion-a-year drug in the making, depending on how the competitive ...

Viking Therapeutics (VKTX) stock falls after Roche (RHHBY) posted promising Phase 1 results for its experimental obesity ...

So it's important to find stocks that can beat the market (hopefully by a large margin) over the long run. That's not easy to do, but here are two stocks in the biotech industry to look at: Viking ...

Viking Therapeutics's VKTX short percent of float has risen 17.0% since its last report. The company recently reported that ...

Viking Therapeutics VKTX, a clinical-stage company focused on developing novel therapeutics for metabolic and endocrine disorders, has been in the news, owing to updates from its obesity program.